MAXONA Pharmaceuticals today announced the preliminary results of the Phase 1 clinical program for MAX-001, which is in development as a New Molecular Entity (NME), non-opioid, non-NSAID oral therapy ...
With this latest addition, the company now boasts five Method of Use and Composition of Matter patents protecting the development and application of MAX-001’s active ingredient, nefopam.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback